CorMedix Inc (CRMD) Price

CorMedix Projects 613% Sales Growth, Edging Out Puma Bio Despite Stock Rally

CorMedix projects 613% sales growth for 2025, positioning it as a potentially stronger investment than Puma Biotechnology, whose stock has rallied 66.7% on weaker fundamentals.

CorMedix Acquires Melinta To Diversify Portfolio

CorMedix has acquired Melinta Therapeutics for $300 million, a strategic move to diversify its product portfolio beyond its primary revenue driver, DefenCath. The acquisition leverages strong sales performance and reflects a broader trend of targeted M&A across the pharmaceutical and medical technology sectors.

Analysts Spotlight Undervalued Small-Cap Stocks for Growth Potential in AI and Diversified Sectors